What is MGI?
MGI Tech Co., Ltd. operates at the intersection of advanced engineering and molecular biology. As a member of the BGI Group, the company specializes in the development and manufacturing of high-throughput genetic sequencing devices, mass spectrometry equipment, and medical imaging tools. By integrating these diverse technologies, MGI provides a comprehensive multi-omics ecosystem that supports life science research, clinical diagnostics, and personalized healthcare. Its market position is defined by a commitment to lowering the barrier to entry for genomic data, thereby enabling researchers and clinicians to access real-time, actionable insights throughout the human life cycle.
How much funding has MGI raised?
MGI has raised a total of $1.4B across 3 funding rounds:
Series A
$200M
Unspecified
$200M
Series B
$1B
Series A (2019): $200M with participation from Green Pine Capital Partners, CITIC Securities, and Orient Securities Capital Investment
Unspecified (2019): $200M led by Green Pine Capital Partners, Orient Securities Capital Investment, and CITIC Goldstone Capital
Series B (2020): $1B supported by CPA and IDG Capital co
Key Investors in MGI
Green Pine Capital Partners
A venture capital firm established in 2007 that provides investment and project management services, focusing on high-growth technology sectors in China.
CITIC Securities
A leading financial services provider founded in 1995, offering comprehensive investment banking and capital market solutions to large-scale enterprises.
IDG Capital
A global investment firm with a long history of backing innovative technology and healthcare companies through various stages of growth.
What's next for MGI?
With the recent influx of capital, MGI is well-positioned to deepen its investment in R&D, specifically targeting the next generation of sequencing throughput and diagnostic precision. The company is expected to leverage these resources to expand its international footprint, particularly in markets where the demand for affordable, high-fidelity genomic data is surging. Strategic priorities likely include the enhancement of its consumable supply chain and the integration of AI-driven analytics into its existing hardware platforms. As MGI transitions into this mature phase of enterprise operations, the focus will shift toward establishing long-term partnerships with global healthcare providers and research institutions to standardize its multi-omics solutions in clinical settings.
See full MGI company page
